Melanoma

When combined with anti-PD-L1 monoclonal antibodies, the treatment achieved synergistic tumor regression, improved effector T cell function, and induced durable immunological memory, demonstrating significant inhibition of both primary and distant tumors in murine models. Collectively, this work presents a transdermal brachytherapeutic-immunomodulatory strategy for melanoma treatment, offering promising potential for enhanced antitumor immunotherapy.

Pharmacological inhibition of PKA and CREB markedly attenuated tinosporide-induced melanogenesis, confirming the essential role of the cAMP/PKA/CREB-MITF axis. Collectively, these findings identify tinosporide as a promising natural melanogenic agent derived from Tinospora cordifolia and highlight its potential relevance in the development of plant-based interventions for hypopigmentation disorders.

This study firstly identified LAG-3 as a pro-tumor factor and a predictor for anti-LAG-3 immunotherapy efficacy. Combined CXCL1/8-CXCR2 inhibitor and anti-LAG-3 treatment may represent a promising therapeutic strategy for LAG-3-driven tumor.

P1, N=41, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Terminated; The trial was terminated for strategic reasons. The decision was not based on any safety concerns.

P4, N=50, Recruiting, Replimune Inc. | Phase classification: P --> P4

Analytical power analysis revealed that for most treatments and/or cancer types, the cohort sizes remain underpowered. Systematic identification of nonresponse signals reveals multiple potential biomarkers that will require larger cohort sizes for prospective clinical implementation.

P1, N=65, Active, not recruiting, Genentech, Inc. | Trial completion date: Jun 2027 --> Dec 2026 | Trial primary completion date: Jun 2027 --> Dec 2026

P1, N=75, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

The e-DAM study demonstrates expert consensus that AMBLor™ could augment clinical decision making at key junctures in the cMM care pathway by refining SLNB selection, rationalising adjuvant therapy and imaging, and reducing follow-up burdens - enhancing personalised care, whilst alleviating service pressures.

An ICB-resistant B16F10 melanoma tumor model was established, and we further verified that the combined treatment with MerTK inhibitor UNC2025 and anti-mouse PD-1 recombinant mAb effectively restored the ICB treatment efficacy...Our findings indicate that [68Ga]Ga-MerTKi PET can potentially identify patients who may benefit from ICB therapy alone and who may need combination therapy. This observation supports the use of MerTK PET as a tool to guide more personalized treatment in cancer immunotherapy.